An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors
Study of IDE397 in Patients with Advanced Solid Tumors
Sponsor: Ideaya
Enrolling: Male and Female Patients
IRB Number: AAAT7435
U.S. Govt. ID: NCT04794699
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not on the market (available for you to receive a prescription for and/or to buy) in any country. The main goals of the study are to determine the safety, tolerability, and effects of IDE397 used as a single agent and in combination with chemotherapy on certain types of cancer. As a single agent, different dose levels of IDE397 will be tested. Different groups of subjects will be treated with increasing dose levels. Every time a dose level is found to be safe, a new dose level will be tested in a new group of subjects until the most appropriate dose is determined. Subjects in the lower dose level may receive IDE397 at the next dose level that is determined to be safe. Once the appropriate dose is determined, further study will aim to determine if this dose is safe and helpful in subjects with certain cancers. Different dose levels of IDE397 will also tested in combination with chemotherapy. Cancers include bladder cancer, breast cancer, colon and rectal cancer, liver cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, and stomach cancer.
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have advanced solid tumors? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator